| Page 49 | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.

Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria

Author(s): 
Brodsky RA, Peffault de Latour R, Rottinghaus ST, Röth A, Risitano AM, Weitz IC, Hillmen P, Maciejewski JP, Szer J, Lee JW, Kulasekararaj AG, Volles L, Damokosh AI, Ortiz S, Shafner L, Liu P, Hill A, Schrezenmeier H
Primary Author: 
Brodsky RA
Journal Title: 
Haematologica
Original Publication Date: 
Jan 2020

Eculizumab is first-line treatment for

Bone Marrow Disease(s): 

Ashley and Alayna: A Mother's Story

Person's Name: 
Ashley Numbers

September 16 through December 20 will stand out in Ashley’s mind.

Forever.

These are the days she spent in the hospital with her feisty three-year-old, Alayna, for conditioning and bone marrow transplant.

The summer of 2019 was already big with a wedding to plan.  The toddler and her baby brother were enjoying everything that small ones do, including riding dirt bikes with Daddy.

Bone Marrow Disease(s): 
Content source: 

Haploidentical transplantation and posttransplant cyclophosphamide for treating aplastic anemia patients: a report from the EBMT Severe Aplastic Anemia Working Party

Author(s): 
Prata PH, Eikema DJ, Afansyev B, Bosman P, Smiers F, Diez-Martin JL, Arrais-Rodrigues C, Koc Y, Poiré X, Sirvent A, Kröger N, Porta F, Holter W, Bloor A, Jubert C, Ganser A, Tanase A, Ménard AL, Pioltelli P, Pérez-Simón JA
Primary Author: 
Prata PH
Journal Title: 
Bone Marrow Transplantation
Original Publication Date: 
Dec 2019

In the absence of an HLA-matched donor, the best treatment for acquired

Bone Marrow Disease(s):